| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0959-8049(97)00040-3 |
| P698 | PubMed publication ID | 9291814 |
| P2093 | author name string | Thoresen SO | |
| Nordal RR | |||
| P2860 | cites work | Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976-1985. | Q34385830 |
| A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas | Q40814312 | ||
| Uterine leiomyosarcoma | Q41661728 | ||
| Uterine sarcoma: analysis of prognostic variables in 71 cases | Q41774278 | ||
| Uterine sarcoma in Israel: a study of 104 cases | Q44050686 | ||
| Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases | Q44125202 | ||
| Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study | Q44739811 | ||
| Uterine sarcomas: natural history, treatment and prognosis | Q67390563 | ||
| Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936-1981 | Q68773219 | ||
| A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study | Q69905277 | ||
| Uterine sarcoma: an analysis of 74 cases | Q70168555 | ||
| Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas | Q70201706 | ||
| Leiomyosarcoma of the uterus | Q70387151 | ||
| Leiomyosarcoma of the uterus | Q70533517 | ||
| Uterine sarcomas: A clinicopathologic study, 1965–1981 | Q72385734 | ||
| P433 | issue | 6 | |
| P921 | main subject | Norway | Q20 |
| P304 | page(s) | 907-911 | |
| P577 | publication date | 1997-05-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. | |
| P478 | volume | 33 |
| Q30370631 | A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study |
| Q37360218 | A rare presentation of acute heart failure secondary to aggressive uterine leiomyosarcoma metastatic to the myocardium initially diagnosed as hypertrophic obstructive cardiomyopathy |
| Q33929694 | Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature |
| Q46253882 | Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. |
| Q44948609 | Clinicopathologic analysis of uterine sarcomas from a single institution in the Canary Islands. |
| Q33430129 | Curative effect of bevacizumab combined with chemotherapy in advanced or recurrent uterine sarcoma |
| Q38758661 | Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey |
| Q27013559 | Current and future options in the management and treatment of uterine sarcoma |
| Q36929175 | Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines |
| Q34336818 | Diagnosis and treatment of sarcoma of the uterus. A review |
| Q55312911 | Diagnostic value of hysteroscopy in abnormal uterine bleeding. |
| Q83223368 | Do DNA copy number changes differentiate uterine from non-uterine leiomyosarcomas and predict metastasis? |
| Q38417643 | Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus |
| Q44608434 | Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation |
| Q35538338 | Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas |
| Q48179788 | Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors |
| Q43274051 | Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles |
| Q36046233 | Imatinib mesylate and its potential implications for gynecologic cancers |
| Q37821354 | Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers |
| Q77373330 | Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Català-Occità |
| Q81101590 | Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma |
| Q37321825 | Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression. |
| Q34516506 | Nationwide surveillance in uterine cancer: survival analysis and the importance of birth cohort: 30-year population-based registry in Taiwan |
| Q34587857 | Novel uterine sarcoma preoperative diagnosis score predicts the need for surgery in patients presenting with a uterine mass |
| Q48514865 | Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study. |
| Q33397997 | Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma |
| Q35619604 | Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. |
| Q28069514 | Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement |
| Q46972704 | Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. |
| Q53539241 | Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. |
| Q92733377 | Recurrent Cervical Sarcoma Botryoides in a 3-Year-Old Female: Approach in a Limited Resource Setting |
| Q35094519 | Relapsing uterine leiomyosarcoma: report of a case |
| Q35150629 | Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy |
| Q39631324 | Second primary malignancies among women with uterine sarcoma |
| Q47196603 | Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas? |
| Q35180929 | Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG |
| Q46320562 | Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. |
| Q34212950 | Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage |
| Q37392149 | Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature. |
| Q37780985 | The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review |
| Q21245577 | Treatment of early uterine sarcomas: disentangling adjuvant modalities |
| Q48107255 | Trends of uterine carcinosarcoma in the United States |
| Q90094159 | Unexpected Histopathological Diagnosis of Undifferentiated Uterine Sarcoma after Simple Hysterectomy: Extrapolating Limited Evidence |
| Q30300308 | Uterine carcinosarcoma: A review of the literature |
| Q37553880 | Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience |
| Q30235911 | Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation |
| Q38098457 | Uterine sarcoma-current management and experience from a regional cancer centre in North India |
| Q47373000 | Uterine sarcoma: twenty-seven years of experience |
| Q86954928 | Uterine sarcomas 2013 |
| Q44608405 | Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT |
| Q90081488 | Utility of diffusion-weighted and contrast-enhanced magnetic resonance imaging in diagnosing and differentiating between high- and low-grade uterine endometrial stromal sarcoma |
| Q64049161 | [Role of adjuvant therapy in uterine sarcoma: experience of the Curie Institute] |
| Q84046048 | [Uterine sarcoma treatment] |
| Q80186250 | [Uterine sarcomas: clinical and therapeutic aspects (10 cases)] |
Search more.